CXCL8 and renal cell carcinoma: Indeed, increased IL-8 in plasma and tumors of RCC patients has been correlated with reduced responsiveness to PD-L1 therapy, and here, we similarly observed increased circulating IL-8 in RCC patients who are non-responders to nivolumab/ipilimumab combination.